High‐affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis
British Journal of Pharmacology2014Vol. 172(7), pp. 1769–1782
Citations Over TimeTop 24% of 2014 papers
Bénédicte Oxombre, Catalina Lee-Chang, Alain Duhamel, Magali Toussaint, M Giroux, Marion Donnier‐Maréchal, Pascal Carato, D. Lefranc, Hélène Zéphir, Lionel Prin, Patricia Melnyk, Patrick Vermersch
Abstract
This σ1 protein agonist, containing the tetrahydroisoquinoline-hydantoin structure, decreased the magnitude of inflammation in EAE. This effect was associated with increased proportions of B-cell subsets and regulatory T-cells with potential immunoregulatory functions. Targeting of the σ1 protein might thus provide new therapeutic opportunities in MS.
Related Papers
- → Sex differences in experimental autoimmune encephalomyelitis in multiple murine strains(2004)148 cited
- → Suppression of MOG- and PLP-induced experimental autoimmune encephalomyelitis using a novel multivalent bifunctional peptide inhibitor(2013)24 cited
- → Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides.(1990)140 cited
- → Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein.(1996)82 cited
- → Targeting myelin proteolipid protein to the MHC class I pathway by ubiquitination modulates the course of experimental autoimmune encephalomyelitis(2008)5 cited